Aurintricarboxylic acid inhibits influenza virus neuraminidase
- PMID: 19014974
- PMCID: PMC7114187
- DOI: 10.1016/j.antiviral.2008.10.006
Aurintricarboxylic acid inhibits influenza virus neuraminidase
Abstract
There is a continuing threat that the highly pathogenic avian influenza virus will cause future influenza pandemics. In this study, we screened a library of compounds that are biologically active and structurally diverse for inhibitory activity against influenza neuraminidase (NA). We found that aurintricarboxylic acid (ATA) is a potent inhibitor of NA activity of both group-1 and group-2 influenza viruses with IC(50)s (effective concentration to inhibit NA activity by 50%) values at low micromolar concentrations. ATA was equally potent in inhibiting the NA activity derived from wild-type NA and its H274Y mutant which renders NA resistance to inhibition by oseltamivir. Although ATA is structurally distinct from sialic acid, molecular modeling experiments suggested that ATA binds to NA at the enzyme's substrate binding site. These results indicate that ATA may be a good starting material for the design of a novel class of NA inhibitors for the treatment influenza viruses.
Figures





Similar articles
-
Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases.PLoS One. 2009 Dec 17;4(12):e8350. doi: 10.1371/journal.pone.0008350. PLoS One. 2009. PMID: 20020057 Free PMC article.
-
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625765 Free PMC article.
-
Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.Antiviral Res. 2008 Feb;77(2):163-6. doi: 10.1016/j.antiviral.2007.08.008. Epub 2007 Sep 10. Antiviral Res. 2008. PMID: 17919743
-
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. ChemMedChem. 2012. PMID: 22807317 Review.
-
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Expert Rev Anti Infect Ther. 2011. PMID: 21973296 Review.
Cited by
-
Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20. doi: 10.1128/AAC.00872-20. Print 2020 Aug 20. Antimicrob Agents Chemother. 2020. PMID: 32669265 Free PMC article.
-
Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition.Antiviral Res. 2009 Jul;83(1):28-34. doi: 10.1016/j.antiviral.2009.03.001. Epub 2009 Mar 14. Antiviral Res. 2009. PMID: 19501254 Free PMC article.
-
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.Antimicrob Agents Chemother. 2009 Oct;53(10):4433-40. doi: 10.1128/AAC.00334-09. Epub 2009 Aug 3. Antimicrob Agents Chemother. 2009. PMID: 19651908 Free PMC article.
-
The inhibitory effect of 7,7″-dimethoxyagastisflavone on the metastasis of melanoma cells via the suppression of F-actin polymerization.Oncotarget. 2016 Jul 30;8(36):60046-60059. doi: 10.18632/oncotarget.10960. eCollection 2017 Sep 1. Oncotarget. 2016. PMID: 28947953 Free PMC article.
-
An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation.Prog Biophys Mol Biol. 2021 Aug;163:143-159. doi: 10.1016/j.pbiomolbio.2021.02.004. Epub 2021 Mar 3. Prog Biophys Mol Biol. 2021. PMID: 33675849 Free PMC article.
References
-
- Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Ther. 2006;11:971–976. - PubMed
-
- Andrew D.J., Hay A.W., Evans S.W. Aurintricarboxylic acid inhibits apoptosis and supports proliferation in a haemopoietic growth-factor dependent myeloid cell line. Immunopharmacology. 1999;41:1–10. - PubMed
-
- Balzarini J., Mitsuya H., De Clercq E., Broder S. Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem. Biophys. Res. Commun. 1986;136:64–71. - PubMed
-
- Baz M., Abed Y., Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 2007;74:159–162. - PubMed
-
- Beery R., Haimsohn M., Wertheim N., Hemi R., Nir U., Karasik A., Kanety H., Geier A. Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue. Endocrinology. 2001;142:3098–3107. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials